This invention relates generally to the field cardiac valve repair, and specifically to systems and methods to control the dimension of a heart valve.
Cardiovascular disease accounts for nearly fifty percent of deaths in both the developed world and in developing countries. Indeed, the risk of dying from heart disease is greater than the risk from AIDS and all forms of cancer combined. Worldwide, cardiovascular disease causes 12 million deaths each year. It is the leading cause of death in the U.S., killing some 950,000 people each year. It also accounts for a significant amount of disability and diminished quality of life. Some 60 million people in the U.S. alone have some form of heart disease. Therefore, a great need exists for the advancement of devices and procedures to cure, treat, and correct a wide variety of forms of heart disease.
Normal heart function primarily relies upon the proper function of each of the four valves of the heart, which pass blood through the four chambers of the heart. The four chambers of the heart include the right atrium and left atrium, the upper chambers, and the right ventricle and left ventricle, the lower chambers. The four valves, controlling blood flow in the chambers, include the tricuspid, mitral, pulmonary, and aortic valves. Heart valves are complex structures that rely on the interaction of many components to open and close the valve. More particularly, each of the four valves of the heart have cusps or leaflets, comprised of fibrous tissue, which attach to the walls of the heart and aid in controlling the flow of blood through the valves. The mitral valve has two leaflets and the tricuspid valve has three leaflets. The aortic and pulmonary valves have three leaflets that are more aptly termed “cusps,” stemming from their half moon shape.
The cardiac cycle involves the pumping and distribution of both oxygenated and deoxygenated blood within the four chambers. In systole, or the rhythmic contraction of the heart cycle, oxygenated blood, enriched by the lungs, enters the heart into the left atrium or left upper chamber. During diastole, or the resting phase of heart cycle, the left atrial pressure exceeds the left ventricle pressure; thus, oxygenated blood flows through the mitral valve, a one way inflow valve, into the left ventricle. The contraction of the left ventricle pumps the oxygenated blood through the aortic valve, into the aorta, and is passed on to the body. When the left ventricle contracts in systole, the mitral valve closes and the oxygenated blood passes into the aorta. Deoxygenated blood returns from the body via the right atrium. This deoxygenated blood flows through the tricuspid valve into the right ventricle. When the right ventricle contracts, the tricuspid valve closes and the deoxygenated blood is pumped through the pulmonary valve. Deoxygenated blood is directed to the pulmonary vascular bed for oxygenation, and the cardiac cycle repeats itself.
The performance of the cardiac cycle by the various components of the heart is a complex and intricate process. Deficiency in one of the components of the heart or deficiency in the performance of the cardiac cycle most often leads to one or more of the numerous different types of heart disease. One of the most prevalent heart disease conditions is mitral valve regurgitation. Mitral valve regurgitation has many levels of severity. After 55 years of age, some degree of mitral regurgitation is found in almost 20% of men and women who have an echocardiogram. Mitral valve regurgitation, or mitral regurgitation, is a condition in which the mitral valve does not close tightly, thereby allowing blood to flow backward in your heart.
In a normal mitral valve, when the atrial pressure exceeds the ventricular pressure, the valve leaflets open into the ventricle. When the ventricle pressure increases, the leaflets meet and close, covering the area of the valve annulus. Therefore, in the diagram shown in
The function of an atrioventricular valve, like the mitral valve, involves the complex interaction of numerous components, including the leaflets, chordae tendineae, and the papillary muscles. If one of the components or functions of the complicated interaction fails, then mitral valve regurgitation can result. For example, excess leaflet tissue, inadequate leaflet tissue, or restricted motion of the leaflets can lead to mitral regurgitation. Prolonged and/or severe mitral valve regurgitation can result in an overworked left ventricle. Overworking the left ventricle can lead to left ventricle enlargement and dysfunction resulting in heart failure. Mitral valve regurgitation is a progressive condition that, if not corrected, can be fatal.
Surgical treatment of ischemic mitral regurgitation (IMR) continues to be hampered by suboptimal clinical results and excessive long-term mortality. Mitral valve repair is preferred to valve replacement for most causes of mitral regurgitation but remains challenging for patients with IMR. Currently, small ring annuloplasty represents the standard mitral repair technique for IMR. Newer reparative techniques have been proposed to address this challenging disease.
U.S. Pat. No. 7,087,064 to Hyde (“'064 patent”) describes a conventional technique for the treatment of mitral valve regurgitation, involving the use of a percutaneously deployable ligament.
As an alternative to the passive ligature method of the '064 patent, an experimental technique of Septal-Lateral Annular Cinching (SLAC) with a central transannular suture has shown some positive results. SLAC presents many potential advantages in comparison to more conventional techniques of treating heart dysfunctions and avoiding congestive heart failure. Conventional approaches and devices of treatment of the mitral valve have often resulted in a modification of the normal function of the valve. For example, some techniques treat mitral valve regurgitation by freezing the posterior leaflet of the valve, thus converting the bi-leaflet valve into a uni-leaflet valve. In a non-limiting example, ring annuloplasty can prevent acute ischemic mitral regurgitation, but it also abolishes normal mitral annular and posterior leaflet dynamics. Ring annuloplasty, and other similar techniques, can lead to the deterioration of the performance of the mitral valve, including a loss of annular flexibility and the creation of a transvalvular gradient. This type of technique modifies or alters the normal function of the mitral valve. SLAC, on the other hand, can be implemented to preserve the physiologic dynamics of the mitral valve and its leaflets. Furthermore, SLAC can help to maintain the physiologic mitral annular morphology for proper function.
A recent study focused on the use of a conventional SLAC implementation to treat acute ischemic mitral regurgitation in animal hearts, illustrated the potential advantages offered by SLAC techniques. Timek T A et al., J Thorac Cardiovasc Surg., 2002 May; 123(5):881-8. The results of the study illustrated an average of a 22% (+/−10%) reduction in mitral annular septal-lateral dimension. This study concluded that this reduction in dimension reduced the acute ischemic mitral regurgitation while allowing near-normal mitral annular and posterior leaflet dynamic motion. Furthermore the study postulated that SLAC may represent a simple method for the surgical treatment of ischemic mitral regurgitation, either as an adjunctive technique or alone, which helps preserve physiologic annular and leaflet function.
Another conventional SLAC technique is disclosed in U.S. Patent Publication No. 2005/0143811 to Realyvasquez (“'811 Publication”). The '811 Publication discloses the implementation of SLAC using percutaneous deployment.
The device 50 disclosed in the '811 Publication includes a ratchet mechanism 60. This ratchet mechanism can be activated by the catheter that delivered the device 50. The '811 Publication describes that the catheter attached to ratchet mechanism 60 is turned in a counter clockwise direction, activating the ratchet mechanism 60. The rotation of the ratchet mechanism 60 operates to move the two wired stents 52 toward the center of the device 50. The '811 Publication discloses that the reduction in the distance between two wired stents 42 attached to the anterior annulus and the posterior annulus will serve to achieve the effect of septal-lateral annular cinching.
While the devices of the prior art are suitable for their intended purposes, they suffer from many drawbacks and fail to meet the demands of interventional cardiologists, cardiovascular surgeons, and the patients on whom they operate. Significantly, a need still exists for a minimally invasive device and associated technique to correct a deficient heart valve. More particularly, a need exists for a minimally invasive device and associated technique to restrict the septal-lateral diameter of an atrioventricular valve. Furthermore, the minimally invasive device and associated technique must be capable of implementation on a beating heart. It is highly desired to have a device capable of restricting the septal-lateral diameter of an atrioventricular valve which can be implemented in a variety of methods, including thoracoscopically and percutaneously.
Therefore, it would be advantageous to provide an apparatus and method for improving valve competence.
Additionally, it would be advantageous to provide an apparatus and method for restricting the dimension of a heart valve.
Additionally, it would be advantageous to provide an apparatus and method for correcting mitral valve regurgitation by restricting the diameter of a heart valve in a beating heart.
Additionally, it would be advantageous to provide an apparatus and method for restricting the diameter of a valve of a beating heart capable of being implemented in a minimally invasive manner.
Additionally, it would be advantageous to provide an apparatus delivered with a long arm or steerable needle from outside the heart for restricting the diameter of a valve of a beating heart.
Additionally, it would be advantageous to provide an apparatus capable of incrementally decreasing the septal-lateral diameter of an atrioventricular valve of a beating heart.
Additionally, it would be advantageous to provide an apparatus capable of decreasing the diameter of a heart valve in increments over an extended period of time.
Additionally, it would be advantageous to provide a method of reducing the dimension of a heart valve that enables a surgeon to easily access components used in an earlier surgery to later further restrict the dimension of the heart valve.
Additionally, it would be advantageous to provide a method of reducing the dimension of a heart valve that allows repeat reductions over an extended period of time.
Additionally, it would be advantageous to provide an apparatus and method for improving the morphology of beating heart valve without altering the physiologic dynamics of the heart valve.
The present invention describes methods and apparatus to control the dimension of a heart valve. An exemplary embodiment of the present invention provides a method of improving valve morphology. The method first involves attaching an anchoring component to a first target site on a tissue component of a heart. Then, a locking component is attached to a second target site on the tissue component of the heart. Subsequently, a tension member is coupled to the anchoring component and the tension member is coupled to the locking component. Then the distance between the first target site and the second target site is adjusted by activating the tension member. The tension member can then be locked into place with the locking component.
These and other objects, features and advantages of the present invention will become more apparent upon reading the following specification in conjunction with the accompanying drawing figures.
The present invention addresses the deficiencies in the prior art by providing a minimally invasive apparatus and method for improving valve morphology. The medical device and method of improving valve morphology disclosed herein can enable an incremental reduction in the distance between two target sites within a valve in the heart. The reduction in the distance between two target sites within a valve in the heart can improve and/or restore the competence of the valve.
An exemplary embodiment of the present invention provides a method of improving valve morphology. The method first involves attaching an anchoring component to a first target site on a tissue component of a heart. Then, a locking component is attached to a second target site on the tissue component of the heart. Subsequently, a tension member is coupled to the anchoring component and the tension member is coupled to the locking component. Then the distance between the first target site and the second target site is adjusted by activating the tension member. The tension member can then be locked into place with the locking component.
An exemplary embodiment of the method of improving valve morphology can be used to treat, and in some instances correct, mitral valve regurgitation. For example, and not limitation, the shortening of the distance between the first target site and the second target site can reduce the septal-lateral diameter of a mitral valve. This reduction in the septal-lateral diameter of a mitral valve can help achieve mitral competence by enabling the overlap of mitral leaflets during systole. Furthermore, the reduction in the septal-lateral diameter can cease or aid in reducing the backflow of blood into the left atrium from the left ventricle during systole.
In addition, to improving the morphology of a mitral valve, the methods and devices enabled by the present invention can be used to improve the competence of other valves. An exemplary embodiment of the method of improving valve morphology can be used to treat, and in some instances correct, aortic valve regurgitation. Alternative embodiments of the method of improving valve morphology can be used to improve the competence of the pulmonic valve and the tricuspid valve.
The method of improving valve morphology in accordance with the present invention is a minimally invasive procedure that can be implemented on a beating heart. Furthermore, the method of improving valve morphology in accordance with the present invention can implemented by a variety of procedures or a combination of a variety of procedures, including thoracoscopic, endovascular, and percutaneous deployment. Those of skill in the art will appreciate that the embodiments of the methods of improving valve morphology and the associated apparatus described herein are exemplary embodiments and have merely been provided as representative examples.
In an exemplary embodiment of the present invention, a cinching apparatus is provided that has an anchoring component with a proximal end and a distal end. The proximal end of the anchoring component has an attaching member enabled to communicate with a tissue component of a heart. The locking component also has an attaching member enabled to communicate with the tissue component of a heart. The cinching apparatus also provides a tension member. The anchoring component is enabled to be positioned on a first target site of a tissue component of the heart, the locking component is enabled to be positioned on a second target site of the tissue component of the heart, and the tension member can be coupled to both the anchoring component and the locking component. The tension member can be activated to adjust the distance between the first target site and the second target site and fixed by the locking component.
In an exemplary embodiment, the tension member is activated by pulling the tension member to adjust the distance in a manner that reduces the distance between the first target site and the second target site. For example, and not limitation, a surgeon could pull the tension member so as to reduce the distance and the lock the tension member into place.
An exemplary embodiment of the cinching apparatus includes one or more anchoring components, locking components, and tension members. The components can be utilized in the method of improving valve morphology in accordance with the present invention. In the exemplary embodiment, the various elements of the cinching apparatus are composed of a biocompatible material. The biocompatible material can be, but is not limited to, biocompatible metals or biocompatible polymers. Those of skill in the art will appreciate that the cinching apparatus could be constructed of a wide variety of biocompatible materials, without detracting from the scope of the invention.
The anchoring component is a device capable of attachment to tissue. In an exemplary embodiment, the anchoring component has a proximal end and a distal end. The terms proximal and proximate are used herein to describe a position which is in the relative vicinity of another position, including a range of vicinity positions through and including being directly adjacent or abutting another position. The term distal is used herein to describe a position which is situated a relative distance away from another position. Thus, the terms proximal/proximate and distal are used herein as spatial relation references and are not used to describe positions upstream or downstream in the flow of blood.
The proximal end of the anchoring component, in exemplary embodiment, can be enabled to engage tissue. For example, and not limitation, the proximal end of the anchoring component is a surface or rod at an angle with the main body of the anchoring component. The angle of the surface or rod allows this surface to produce interference, or clamp onto, a tissue component. In alternative embodiment, the anchoring component can have a proximal end with an umbrella configuration capable of piercing a tissue surface. Another embodiment provides an anchoring component with legs capable of embedding into a tissue surface. Those of skill in the art will appreciate that the proximal end of the anchoring component could be a variety of different components capable of attaching to a tissue surface.
In an exemplary embodiment, the central section of the anchoring system is a rod, wire, or many suitable elongated bodies. On the distal side of the anchoring component there is an engaging member or surface. This member is designed to couple with the tension member or rod. The coupling member in its preferred embodiments is a loop, a screwing surface, a hook, a clamp, a docking orifice, or many other suitable components. The anchoring component can be delivered endovascularly using a catheter or through a porthole in a heart chamber using a long arm delivery device or a steerable needle. Those of skill in the art will appreciate that the devices and tools used to implement the methods of the present invention can vary with the type of implementation. For example, those of skill in the art will appreciate that a long arm device can many different types of devices which enable a minimally invasive delivery of a component.
The anchoring device 400A shown in
In an exemplary embodiment, the locking component 605 can be attached at many suitable target sites on a tissue component of the heart. For example, and not limitation, in one embodiment the locking component 605 can be attached to a target site on a mitral annulus which is substantially opposite the location at which an anchoring component has been attached to the mitral annulus. The locking component 605 can have piercing components, such as 620 and 625, to pierce a tissue component and anchor the locking component 605 to the tissue component. In the exemplary embodiment shown in
The locking component 605 can provide a conduit through which a tension member 610 can be passed. In an exemplary embodiment, a tension member 610 can be passed through the locking component 605 and enter the left atrium. In this exemplary embodiment, the tension member 610 can have an engaging distal end that can be coupled to the engaging member 415 of the anchoring component 400A (
In an exemplary embodiment, the locking component 605 is also enabled to be unlocked. Thus, if it is later desired to alter the distance between the locking component 605 and the anchoring component, the tension member 610 can be unlocked from the locking component 605. In a non-limiting example, the tension member 610 can be advanced to further reduce the distance between the locking component 605 and the anchoring component and then locked into place again.
In an alternative embodiment of the method of improving valve morphology, the anchoring component 705 can be delivered through the left atrium 730. In a non-limiting example, the anchoring component 705 can be attached to a catheter and percutaneously deployed into the left atrium 730. After the anchoring component 705 has been introduced into the left atrium 730, it can be caused to pierce the posterior mitral annulus 720 at a target site. In an exemplary embodiment, the attaching member 715 of the anchoring component 705 can be caused to pierce the mitral annulus 720 at a target site and protrude into the left ventricle. In this manner, the anchoring component 705 is lodged onto the posterior mitral annulus 720 at a target site.
Those of skill in the art will appreciate that the exemplary embodiment shown in
For example, and not limitation, the tension member 820 can extend through a long arm device outside of the patient's body. Therefore, the surgeon would have the capability to pull the tension member 820 outside of the patient's body, and thereby reduce the septal-lateral diameter of the mitral valve 830.
Those of skill in the art will appreciate that one or many sets of locking and anchoring components linked by a tension member can be implemented in an atrioventricular valve in accordance with the present invention. In some implementations, only one set of locking and anchoring components linked by a tension member is implanted. Generally, somewhere in the range of two to ten sets of locking and anchoring components linked by a tension member are implemented in an atrioventricular valve.
As shown
In accordance with an exemplary embodiment of the present invention, the locking component can be unlocked. In this manner, it is possible to readjust the dimension of the heart valve treated. In a non-limiting example, the valve diameter can be reduced by a certain amount and then tension member can be locked into place by the locking component. A test can then be performed to determine the competence level of the valve treated. If the competence is not to a desired level, then the tension member can be unlocked from the locking component, pulled further, and re-locked into position. Therefore, an exemplary embodiment of the present invention permits for the incremental reduction of the valve dimension over relatively extended periods of time. In one embodiment, a patient could undergo a supplemental surgery in which the locking components were accessed and the tension members further drawn to increase the reduction of the valve diameter.
The cinching apparatus of the present invention can be implemented in any of the four valves in the heart. Those of skill in the art will appreciate that each type of valve can require its own particular implementation of the cinching apparatus, wherein in the location of the components and their delivery is altered to compensate for the unique characteristics of each of the four valves.
In addition to the ability to mount the anchoring components between the annulus 1230 of the tricuspid valve 1205 and the right ventricle 1220, it is possible to mount the anchoring components between the annulus 1230 and the wall of the right atrium 1225. As shown in
On a substantially opposite side of the annulus 1230 of the tricuspid valve 1205, a locking component 1240 can be provided. In an exemplary embodiment, the locking component 1240 can be delivered via a long arm device to the wall of the right atrium 1225. The locking component 1240 can then caused to pierce the wall of the right atrium 1225. In an exemplary embodiment, a tension member 1245 can be passed through the locking component 1240 and through the annulus 1230 of the tricuspid valve 1205. The tension member 1245 can then be coupled to the engaging members of the anchoring components, 1210 and 1215. Once the tension member 1245 is coupled, it can be advanced to reduce the distance between the anchoring components, 1210 and 1215, and the locking component 1240. Subsequently, the tension member 1245 can be locked into place by the locking component 1240. Thereby, the competence of the tricuspid valve 1205 can be improved by enabling the leaflets of the tricuspid valve 1205 to more completely close.
As illustrated in
While the invention has been disclosed in its preferred forms, it will be apparent to those skilled in the art that many modifications, additions, and deletions can be made therein without departing from the spirit and scope of the invention and its equivalents as set forth in the following claims.
This application is a 35 U.S.C. § 371 U.S. National Stage of International Application No. PCT/US2006/062192 filed 15 Dec. 2006, which claims priority to and the benefit of U.S. Ser. No. 60/750,559, filed 15 Dec. 2005. All of said prior applications are hereby incorporated by reference in their entireties as if fully set forth below. This application claims the benefit of U.S. Provisional Application No. 60/750,559, filed 15 Dec. 2005, which is hereby incorporated by reference in its entirety as if fully set forth below.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2006/062192 | 12/15/2006 | WO | 00 | 10/27/2008 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2007/100409 | 9/7/2007 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3656185 | Carpentier | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
4055861 | Carpentier et al. | Nov 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4164046 | Cooley | Aug 1979 | A |
4217665 | Bex et al. | Aug 1980 | A |
4275469 | Gabbay | Jun 1981 | A |
4602911 | Ahmadi et al. | Jul 1986 | A |
4790844 | Ovil | Dec 1988 | A |
4917097 | Proudian et al. | Apr 1990 | A |
4993428 | Arms | Feb 1991 | A |
5010892 | Colvin et al. | Apr 1991 | A |
5041130 | Cosgrove et al. | Aug 1991 | A |
5061277 | Carpentier et al. | Oct 1991 | A |
5064431 | Gilbertson et al. | Nov 1991 | A |
5104407 | Lam et al. | Apr 1992 | A |
5201880 | Wright et al. | Apr 1993 | A |
5258021 | Duran | Nov 1993 | A |
5306296 | Wright et al. | Apr 1994 | A |
5316016 | Adams et al. | May 1994 | A |
5344442 | Deac | Sep 1994 | A |
5396887 | Imran | Mar 1995 | A |
5450860 | O'Connor | Sep 1995 | A |
5480424 | Cox | Jan 1996 | A |
5496336 | Cosgrove et al. | Mar 1996 | A |
5533515 | Coller et al. | Jul 1996 | A |
5573007 | Bobo, Sr. | Nov 1996 | A |
5593435 | Carpentier et al. | Jan 1997 | A |
5607471 | Seguin et al. | Mar 1997 | A |
5662704 | Gross | Sep 1997 | A |
5674279 | Wright et al. | Oct 1997 | A |
5728064 | Burns et al. | Mar 1998 | A |
5733331 | Peredo | Mar 1998 | A |
5752522 | Murphy | May 1998 | A |
5776189 | Khalid | Jul 1998 | A |
5814098 | Hinnenkamp et al. | Sep 1998 | A |
5824066 | Gross | Oct 1998 | A |
5824069 | Lemole | Oct 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5855563 | Kaplan et al. | Jan 1999 | A |
5865801 | Houser | Feb 1999 | A |
5888240 | Carpentier et al. | Mar 1999 | A |
5902308 | Murphy | May 1999 | A |
5919147 | Jain | Jul 1999 | A |
5921934 | Teo | Jul 1999 | A |
5921935 | Hickey | Jul 1999 | A |
5924984 | Rao | Jul 1999 | A |
5931868 | Gross | Aug 1999 | A |
5972030 | Garrison et al. | Oct 1999 | A |
6010531 | Donlon et al. | Jan 2000 | A |
6019739 | Rhee et al. | Feb 2000 | A |
6024918 | Hendriks et al. | Feb 2000 | A |
6066160 | Colvin et al. | May 2000 | A |
6081737 | Shah | Jun 2000 | A |
6083179 | Oredsson | Jul 2000 | A |
6099475 | Seward et al. | Aug 2000 | A |
6102945 | Campbell | Aug 2000 | A |
6110200 | Hinnenkamp | Aug 2000 | A |
6117091 | Young et al. | Sep 2000 | A |
6143024 | Campbell et al. | Nov 2000 | A |
6159240 | Sparer et al. | Dec 2000 | A |
6165120 | Schweich, Jr. et al. | Dec 2000 | A |
6183512 | Howanec, Jr. et al. | Feb 2001 | B1 |
6187040 | Wright | Feb 2001 | B1 |
6217610 | Carpentier et al. | Apr 2001 | B1 |
6231602 | Carpentier et al. | May 2001 | B1 |
6250308 | Cox | Jun 2001 | B1 |
6258122 | Tweden et al. | Jul 2001 | B1 |
6312464 | Navia | Nov 2001 | B1 |
6332893 | Mortier et al. | Dec 2001 | B1 |
6391054 | Carpentier et al. | May 2002 | B2 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6406493 | Tu et al. | Jun 2002 | B1 |
6409759 | Peredo | Jun 2002 | B1 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6602288 | Cosgrove et al. | Aug 2003 | B1 |
6602289 | Colvin et al. | Aug 2003 | B1 |
6619291 | Hlavka et al. | Sep 2003 | B2 |
6626899 | Houser et al. | Sep 2003 | B2 |
6629534 | St. Goer et al. | Oct 2003 | B1 |
6669687 | Saadat | Dec 2003 | B1 |
6709456 | Langberg et al. | Mar 2004 | B2 |
6718985 | Hlavka et al. | Apr 2004 | B2 |
6719786 | Ryan et al. | Apr 2004 | B2 |
6723038 | Schroeder et al. | Apr 2004 | B1 |
6726715 | Sutherland | Apr 2004 | B2 |
6726717 | Alfieri et al. | Apr 2004 | B2 |
6764510 | Vidlund et al. | Jul 2004 | B2 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6797002 | Spence et al. | Sep 2004 | B2 |
6800090 | Alferness et al. | Oct 2004 | B2 |
6802860 | Cosgrove et al. | Oct 2004 | B2 |
6805710 | Bolling et al. | Oct 2004 | B2 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6830586 | Quijano et al. | Dec 2004 | B2 |
6858039 | McCarthy | Feb 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6908482 | McCarthy et al. | Jun 2005 | B2 |
6918917 | Nguyen et al. | Jul 2005 | B1 |
6921407 | Nguyen et al. | Jul 2005 | B2 |
6942694 | Liddicoat et al. | Sep 2005 | B2 |
6945996 | Sedransk | Sep 2005 | B2 |
6955689 | Ryan et al. | Oct 2005 | B2 |
6966924 | Holmberg | Nov 2005 | B2 |
6986775 | Morales et al. | Jan 2006 | B2 |
6991649 | Sievers | Jan 2006 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7037334 | Hlavka et al. | May 2006 | B1 |
7066954 | Ryan et al. | Jun 2006 | B2 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7112219 | Vidlund et al. | Sep 2006 | B2 |
7118595 | Ryan et al. | Oct 2006 | B2 |
7125421 | Tremulis et al. | Oct 2006 | B2 |
7144363 | Pai | Dec 2006 | B2 |
7166126 | Spence et al. | Jan 2007 | B2 |
7166127 | Spence et al. | Jan 2007 | B2 |
7186262 | Saadat | Mar 2007 | B2 |
7247134 | Vidlund et al. | Jul 2007 | B2 |
7294148 | McCarthy | Nov 2007 | B2 |
7329280 | Bolling et al. | Feb 2008 | B2 |
7527647 | Spence | May 2009 | B2 |
8308765 | Saadat | Nov 2012 | B2 |
20010034551 | Cox | Oct 2001 | A1 |
20020029080 | Mortier et al. | Mar 2002 | A1 |
20020129820 | Ryan et al. | Sep 2002 | A1 |
20020133180 | Ryan et al. | Sep 2002 | A1 |
20020169504 | Alferness et al. | Nov 2002 | A1 |
20020173844 | Alfieri et al. | Nov 2002 | A1 |
20030033009 | Gabbay | Feb 2003 | A1 |
20030040793 | Marquez | Feb 2003 | A1 |
20030078653 | Vesely et al. | Apr 2003 | A1 |
20030083742 | Spence et al. | May 2003 | A1 |
20030093148 | Bolling et al. | May 2003 | A1 |
20030105519 | Fasol et al. | Jun 2003 | A1 |
20040006384 | McCarthy | Jan 2004 | A1 |
20040088047 | Spence et al. | May 2004 | A1 |
20040122513 | Navia et al. | Jun 2004 | A1 |
20040133192 | Houser et al. | Jul 2004 | A1 |
20040152947 | Schroeder et al. | Aug 2004 | A1 |
20040153103 | Schwartz | Aug 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040193259 | Gabbay | Sep 2004 | A1 |
20040249452 | Adams et al. | Dec 2004 | A1 |
20040249453 | Cartledge et al. | Dec 2004 | A1 |
20040260317 | Bloom et al. | Dec 2004 | A1 |
20050004666 | Alfieri et al. | Jan 2005 | A1 |
20050043791 | McCarthy et al. | Feb 2005 | A1 |
20050070999 | Spence | Mar 2005 | A1 |
20050075719 | Berghiem | Apr 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050080402 | Santamore et al. | Apr 2005 | A1 |
20050131533 | Alfieri et al. | Jun 2005 | A1 |
20050137689 | Salahieh et al. | Jun 2005 | A1 |
20050143811 | Realyvasquez | Jun 2005 | A1 |
20050182487 | McCarthy et al. | Aug 2005 | A1 |
20050192666 | McCarthy | Sep 2005 | A1 |
20050197696 | Gomez Duran | Sep 2005 | A1 |
20050246014 | McCarthy | Nov 2005 | A1 |
20050256567 | Lim et al. | Nov 2005 | A1 |
20050256568 | Lim et al. | Nov 2005 | A1 |
20050256569 | Lim et al. | Nov 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20050267572 | Schoon et al. | Dec 2005 | A1 |
20050278022 | Lim | Dec 2005 | A1 |
20050288776 | Shaoulian et al. | Dec 2005 | A1 |
20050288777 | Rhee et al. | Dec 2005 | A1 |
20050288778 | Shaoulian et al. | Dec 2005 | A1 |
20050288780 | Rhee et al. | Dec 2005 | A1 |
20050288782 | Moaddeb et al. | Dec 2005 | A1 |
20050288783 | Shaoulian et al. | Dec 2005 | A1 |
20060015178 | Moaddeb et al. | Jan 2006 | A1 |
20060015179 | Bulman-Fleming et al. | Jan 2006 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060020336 | Liddicoat | Jan 2006 | A1 |
20060025856 | Ryan et al. | Feb 2006 | A1 |
20060025858 | Alameddine | Feb 2006 | A1 |
20060030885 | Hyde | Feb 2006 | A1 |
20060052868 | Mortier et al. | Mar 2006 | A1 |
20060149368 | Spence | Jul 2006 | A1 |
20060167474 | Bloom et al. | Jul 2006 | A1 |
20060195012 | Mortier et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060241340 | Schroeder et al. | Oct 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20070038294 | Navia | Feb 2007 | A1 |
20070049952 | Weiss | Mar 2007 | A1 |
20070050020 | Spence | Mar 2007 | A1 |
20070066863 | Rafiee et al. | Mar 2007 | A1 |
20070100439 | Cangialosi et al. | May 2007 | A1 |
20070118151 | Davidson | May 2007 | A1 |
20070118154 | Crabtree | May 2007 | A1 |
20070118213 | Loulmet | May 2007 | A1 |
20070123979 | Perier et al. | May 2007 | A1 |
20070129758 | Saadat | Jun 2007 | A1 |
20070162111 | Fukamachi et al. | Jul 2007 | A1 |
20070173930 | Sogard et al. | Jul 2007 | A1 |
20070203391 | Bloom | Aug 2007 | A1 |
20070208357 | Houser et al. | Sep 2007 | A1 |
20070213582 | Zollinger et al. | Sep 2007 | A1 |
20070255396 | Douk et al. | Nov 2007 | A1 |
20080027268 | Buckner et al. | Jan 2008 | A1 |
20080039935 | Buch et al. | Feb 2008 | A1 |
20080051807 | St. Goar et al. | Feb 2008 | A1 |
20080081942 | Pai et al. | Apr 2008 | A1 |
20090157174 | Yoganathan et al. | Jun 2009 | A1 |
20090177278 | Spence | Jul 2009 | A1 |
20090192602 | Kuehn | Jul 2009 | A1 |
20090192603 | Ryan | Jul 2009 | A1 |
20090192604 | Gloss | Jul 2009 | A1 |
20090192605 | Gloss et al. | Jul 2009 | A1 |
20090192606 | Gloss et al. | Jul 2009 | A1 |
Number | Date | Country |
---|---|---|
0338994 | Oct 1989 | EP |
0595791 | May 1994 | EP |
0860151 | Aug 1998 | EP |
1034753 | Sep 2000 | EP |
2708458 | Aug 1993 | FR |
199119456 | Dec 1991 | WO |
199503757 | Feb 1995 | WO |
199640006 | Dec 1996 | WO |
199741801 | Nov 1997 | WO |
199742871 | Nov 1997 | WO |
199806329 | Feb 1998 | WO |
199911201 | Mar 1999 | WO |
WO 199930647 | Jun 1999 | WO |
199951169 | Oct 1999 | WO |
199965423 | Dec 1999 | WO |
200032105 | Jun 2000 | WO |
WO 2000047139 | Aug 2000 | WO |
200119292 | Mar 2001 | WO |
200126586 | Apr 2001 | WO |
200147438 | Jul 2001 | WO |
200187191 | Nov 2001 | WO |
200203892 | Jan 2002 | WO |
2003020178 | Mar 2003 | WO |
2003041617 | May 2003 | WO |
2004004607 | Jan 2004 | WO |
WO 2004112658 | Dec 2004 | WO |
2005004753 | Jan 2005 | WO |
2005034813 | Apr 2005 | WO |
2005082278 | Sep 2005 | WO |
2005110290 | Nov 2005 | WO |
2006041877 | Apr 2006 | WO |
2006133186 | Dec 2006 | WO |
2007050506 | May 2007 | WO |
2007100408 | Sep 2007 | WO |
WO2007100408 | Sep 2007 | WO |
WO2007100409 | Sep 2007 | WO |
WO2007100410 | Sep 2007 | WO |
2007131513 | Nov 2007 | WO |
2008058940 | May 2008 | WO |
2008063537 | May 2008 | WO |
2008094469 | Aug 2008 | WO |
2008098226 | Aug 2008 | WO |
Entry |
---|
International Search Report and Written Opinion dated Oct. 12, 2007 for related PCT Application No. PCT/US2006/062185. |
International Search Report and Written Opinion dated Sep. 27, 2007 for related PCT Application No. PCT/US2006/062192. |
International Search Report and Written Opinion dated Oct. 31, 2007 for related PCT Application No. PCT/US2006/062199. |
Examination Report for related European Patent Application No. 06850306.9 dated Apr. 8, 2011. |
Adams, David, et al., “Large Annuloplasty Rings Facilitate Mitral Valve Repair in Barlow's Disease”, The Society of Thoracic Surgeons, vol. 82, pp. 2096-2101, 2006. |
Alonso-Lei, F. et al., “Adjustable Annuloplasty for Tricuspid Insufficiency” The Annals of Thoracic Surgery, vol. 46, No. 3, pp. 368-369, Sep. 1988. |
Bolling, Steven F. et al., “Mitral Valve Reconstruction in the Patient with Heart Failure”, Heart Failure Reviews, vol. 6, pp. 177-185, 2001. |
Bolling, Steven F. et al., “Surgical Alternatives for Heart Failure”, The Journal of Heart and Lung Transplantation, vol. 20, No. 7, pp. 729-733, 2001. |
Carpentier, Alain F. et al., “The “Physio-Ring”: An Advanced Concept in Mitral Valve Annuloplasty”, The Thirty-First Annual Meeting of The Society of Thoracic Surgeons, pp. 1177-1186, Jan. 30-Feb. 2, 1995. |
“Carpentier-Edwards Classic Annuloplasty Ring With Duraflo Treatment Models 4425 and 4525 for Mitral and Tricuspid Valvuloplasty”, Baxter Healthcare Corporation, pp. 1-6, 1998. |
“Carpentier-Edwards Physio Annuloplasty Ring”, Edwards Lifesciences LLC, pp. 1-2, 2003. |
Cochran, Richard P. et al., “Effect of Papillary Muscle Position on Mitral Valve Function: Relationship to Homografts”, The Society of Thoracic Surgeons, vol. 66, pp. S155-S161, 1998. |
Flachskampf, Frank A. et al., “Analysis of Shape and Motion of the Mitral Annulus in Subjects With and Without Cardiomyopathy by Echocardiographic 3-Dimensional Reconstruction”, The Journal of the American Society of Echocardiography, vol. 13, pp. 277-287, 2000. |
Gatti, Giuseppe et al., “Preliminary Experience in Mitral Valve Repair Using the Cosgrove-Edwards Annuloplasty Ring”, Interactive Cardiovascular and Thoracic Surgery, vol. 2, No. 3, pp. 256-261, 2003, http://icvts.ctsnetjournals.org/cgi/content/full/2/3/256. |
Melo, J.Q. et al., “Atrioventricular Valve Repair Using Externally Adjustable Flexible Rings”, The Journal of Thoracic and Cardiovascular Surgery, vol. 110, No. 5, pp. 1333-1337, Nov. 1995. |
“MGH Study Shows Mitral Valve Prolapse Not a Stroke Risk Factor”, Massachusetts General Hospital, pp. 1-3, Jun. 1999, http://www.mgh.harvard.edu/DEPTS/pubaffairs/releases/Jun_99_mitral_valve.htm. |
Miller, Craig D., “Ischemic Mitral Regurgitation Redux—To Repair or to Replace?”, The Journal of Thoracic and Cardiovascular Surgery, vol. 22, No. 6, pp. 1059-1062, Dec. 2001. |
Salgo, Ivan S. et al., “Effect of Annular Shape on Leaflet Curvature in Reducing Mitral Leaflet Stress”, Journal of the American Heart Association, Circulation 2002, vol. 106, pp. 711-717, Jul. 22, 2002, http://circ.ahajournals.org/cgi/reprint/106/6/711. |
Seguin, J.R. et al., “Advance in Mitral Valve Repair Using a Device Flexible in Three Dimensions”, The St. Jude Medical-Seguin Annuloplasty Ring, The American Society for Artificial Internal Organs Journal, vol. 42, No. 6, pp. M368-M371, 1996. |
Smolens, Iva A. et al., “Mitral Valve Repair in Heart Failure”, The European Journal of Heart Failure, vol. 2, pp. 365-371, 2000. |
“Techniques for 3D Quantitative Echocardiography”, University of Washington Cardiovascular Research & Training Center Cardiac Imaging Research Lab, pp. 1-4, http://depts.washington.edu/cvrtc/apples.html. |
Watanabe, Nozomi, et al., “Mitral Annulus Flattens in Ischemic Mitral Regurgitation: Geometric Differences Between Inferior and Anterior Myocardial Infarction: A Real-Time 3-Dimensional Echocardiographic Study” Journal of the American Heart Association, Circulation 2005, vol. 112, pp. 458-468, Aug. 30, 2005, http://circ.ahajournals.org/cgi/content/full/112/9_suppI/I-458. |
Number | Date | Country | |
---|---|---|---|
20090292353 A1 | Nov 2009 | US |
Number | Date | Country | |
---|---|---|---|
60750559 | Dec 2005 | US |